PO.MCB07.03 · 分子与细胞生物学

METTL3在结直肠癌中的作用

The roles of METTL3 in colorectal cancer

海报缩略图:METTL3在结直肠癌中的作用
编号 5961 展板 16 时间 4/21 02:00–05:00 区域 Section 22 主讲 Hung Mai, MS;Pharm D
分会场 Mechanisms and Dynamics of Gene Expression
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Hung Mai, Sidi Zhao, DEBANJAN SAHA, Jace Webster, Li Lin, Emily Rozycki, Ashna Agarwal, Muheng Liao, Christopher Maher

Department of Medicine, Washington University, St. Louis, MO

摘要 Abstract

中文摘要
结直肠癌(CRC)是全球癌症相关死亡的主要原因之一,占所有癌症死亡的10%。半数CRC病例发生转移性疾病,5年生存率为14%。因此,理解CRC进展的分子机制对于改善诊断和治疗十分重要。近期研究识别出m6A(N6-甲基腺苷)RNA甲基转移酶METTL3是CRC中的关键致癌基因,提示表观转录组调控在癌症中的重要作用。M6A修饰影响RNA代谢的多个方面,包括降解、输出和翻译。然而,METTL3在CRC中的确切机制仍未明确。我们识别出YTHDF1(一种m6A阅读器)是CRC患者中上调最显著的阅读器。然而,METTL3-YTHDF1在CRC进展中的相互作用尚不清楚。本研究旨在阐明METTL3和YTHDF1如何通过m6A修饰协同促进CRC进展,并识别新的、临床相关的m6A靶点。为此,我们在METTL3敲低的细胞中进行了Nanopore直接RNA测序,以绘制整个CRC转录本中METTL3依赖性的m6A位点图谱。为识别其m6A被YTHDF1读取的基因,我们在METTL3敲低和YTHDF1敲低的细胞中进行了短读长RNA测序,以确定与RNA甲基化相关的共同转录变化。将这些数据集与患者数据整合,揭示了受METTL3和YTHDF1调控的临床相关转录本。选定候选靶点上的m6A富集通过MeRIP-qPCR得到验证。与两个现有m6A数据库的比对证实了重叠位点,并发现了先前未注释的位点。其中,TRIB3(一个已知的CRC致癌基因)在各数据集中一致地成为最重要的m6A靶点,在METTL3或YTHDF1敲低后其表达显著降低。因此,TRIB3被选为进一步研究的概念性靶点。利用RNA免疫沉淀,我们发现YTHDF1与TRIB3相互作用,且这种相互作用在METTL3耗竭后减弱。敲低METTL3或YTHDF1降低了TRIB3的RNA稳定性和多聚核糖体占位,导致转录本和蛋白水平下降。为直接去除TRIB3上的m6A,我们使用了偶联ALKBH5(一种m6A去甲基化酶)的dCasRX,并结合靶向TRIB3的sgRNA。双sgRNA有效去除了TRIB3上的m6A并降低了其表达,证实了m6A在调控TRIB3水平中的功能作用。TRIB3过表达挽救了METTL3敲低细胞中的迁移和侵袭缺陷,而通过dCasRX-ALKBH5去除TRIB3上的m6A则抑制了这些表型,表明METTL3和YTHDF1通过调控TRIB3促进CRC的侵袭和迁移。我们的研究凸显了YTHDF1-TRIB3轴与METTL3协同促进CRC的作用。此外,我们的无偏分析揭示了CRC中其他若干潜在的m6A靶点。这些发现为CRC进展提供了新的见解,并凸显了靶向m6A调控网络的潜在治疗路径。
查看英文原文 English abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, accounting for 10% of all cancer deaths. Metastatic disease occurs in half of all CRC cases, with a 5-year survival rate of 14%. Thus, understanding molecular mechanisms of CRC progression is important for improving diagnostics and therapies. Recent studies identified the m6A (N6-methyladenosine) RNA methyltransferase-METTL3 as a key oncogene in CRC, suggesting the important role of epitranscriptomic regulation in cancer. M6A modification affects multiple aspects of RNA metabolism, including degradation, export, and translation. However, the precise mechanisms of METTL3 in CRC remain undefined. We identified YTHDF1, an m6A reader, as the most upregulated reader in CRC patients. Yet, the METTL3-YTHDF1 interplay in CRC progression is unclear. This study aims to define how METTL3 and YTHDF1 act together to promote CRC progression via m6A modifications, and to identify novel, clinically relevant m6A targets. To achieve this, we performed Nanopore direct RNA-seq in METTL3-knockdown cells to map METTL3-dependent m6A sites across the CRC transcripts. To identify genes whose m6As are read by YTHDF1, we conducted short-read RNA-seq in METTL3- and YTHDF1-knockdown cells to determine shared transcriptional changes associated with RNA methylation. Integrating these datasets with patient data revealed clinically relevant transcripts regulated by METTL3 and YTHDF1. m6A enrichment on selected candidates were validated by MeRIP-qPCR. Comparison with two existing m6A databases confirmed overlapping sites and uncovered previously unannotated sites. Among these, TRIB3 , a known oncogene in CRC, consistently emerged as a top m6A target across datasets, with expression significantly reduced upon METTL3 or YTHDF1 knockdown. Thus, TRIB3 was selected as a conceptual target for further studies. Using RNA immunoprecipitation, we found YTHDF1 interacts with TRIB3 , and this interaction is reduced upon METTL3 depletion. Knockdown of METTL3 or YTHDF1 reduces TRIB3 RNA stability and polysome occupancy causing decreased transcript and protein levels. To directly remove m6As on TRIB3 , we used dCasRX conjugated to ALKBH5, an m6A demethylase, and coupled with sgRNAs targeting TRIB3 . Dual sgRNAs effectively removed m6As on TRIB3 and reduced its expression, confirming functional roles of m6As in regulating TRIB3 level. TRIB3 overexpression rescued migration and invasion defects in METTL3 knockdown cells, while m6A removal on TRIB3 by dCasRX-ALKBH5 suppressed these phenotypes, indicating METTL3 and YTHDF1 promote CRC invasion and migration through TRIB3 regulation. Our study highlights the role of the YTHDF1-TRIB3 axis in cooperating with METTL3 to promote CRC. Additionally, our unbiased analyses reveal several other potential m6A targets in CRC. These findings provide new insights into CRC progression and highlight potential therapeutic paths targeting the m6A regulatory network.
利益披露 Disclosure
H. Mai, None.. S. Zhao, None.. D. Saha, None.. J. Webster, None.. L. Lin, None.. E. Rozycki, None.. A. Agarwal, None.. M. Liao, None.. C. Maher, None.

← 返回 AACR 2026 检索